# OptiNose Inc. (OPTN)

Source: https://www.quantisnow.com/company/OPTN
Generated: 2026-11-16T05:14:09.432Z

- Ticker: OPTN
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2017
- SEC CIK: 0002070577
- Website: optinose.com

## About

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase 3b clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.

## Latest OPTN news and filings

- 2026-03-14 01:31 UTC [SEC Form S-1] [Amendment: SEC Form S-1/A filed by OptiNose Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-1a-filed-by-optinose-inc-6447958)
- 2025-06-02 17:57 UTC [SEC Form 15-12G filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-optinose-inc-6067179)
- 2025-05-22 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-optinose-inc-6053357)
- 2025-05-22 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-optinose-inc-6053355)
- 2025-05-22 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-optinose-inc-6053354)
- 2025-05-22 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-optinose-inc-6053353)
- 2025-05-22 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-optinose-inc-6053352)
- 2025-05-22 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-optinose-inc-6053351)
- 2025-05-22 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-optinose-inc-6053350)
- 2025-05-21 17:50 UTC [SEC Form 25-NSE filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-optinose-inc-6052106)
- 2025-05-21 14:45 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-optinose-inc-6051992)
- 2025-05-21 14:42 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-optinose-inc-6051987)
- 2025-05-21 14:39 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-optinose-inc-6051985)
- 2025-05-21 14:35 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-optinose-inc-6051984)
- 2025-05-21 14:32 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-optinose-inc-6051978)
- 2025-05-21 14:29 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-optinose-inc-6051974)
- 2025-05-21 14:26 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-optinose-inc-6051972)
- 2025-05-21 14:22 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-optinose-inc-6051969)
- 2025-05-21 14:19 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-optinose-inc-6051961)
- 2025-05-21 14:15 UTC [SEC Form POS AM filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-optinose-inc-6051959)
- 2025-05-21 14:11 UTC [SEC Form POS AM filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-optinose-inc-6051954)
- 2025-05-21 14:09 UTC [SEC Form POS AM filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-optinose-inc-6051951)
- 2025-05-21 14:02 UTC [SEC Form POS AM filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-optinose-inc-6051947)
- 2025-05-21 13:59 UTC [SEC Form POS AM filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-optinose-inc-6051944)
- 2025-05-21 13:55 UTC [SEC Form POS AM filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-optinose-inc-6051939)
- 2025-05-21 13:51 UTC [SEC Form POS AM filed by OptiNose Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-optinose-inc-6051937)
- 2025-05-21 13:26 UTC [SEC Form 4] [Chief Legal Officer & Corp Sec Marino Michael F Iii returned 125,204 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-legal-officer-corp-sec-marino-michael-f-iii-returned-6051919)
- 2025-05-21 13:26 UTC [SEC Form 4] [Chief Financial Officer Kohler Terry returned 30,541 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-kohler-terry-returned-30541-shares-to-the-6051917)
- 2025-05-21 13:26 UTC [SEC Form 4] [SEC Form 4 filed by Director Fletcher R John](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-fletcher-r-john-6051916)
- 2025-05-21 13:25 UTC [SEC Form 4] [SEC Form 4 filed by Director Helton Sandra L](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-helton-sandra-l-6051915)
- 2025-05-21 13:25 UTC [SEC Form 4] [SEC Form 4 filed by Director Groenhuysen Wilhelmus Cm](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-groenhuysen-wilhelmus-cm-6051914)
- 2025-05-21 13:25 UTC [SEC Form 4] [Chief Commercial Officer Spence Paul Jr. returned 102,813 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-commercial-officer-spence-paul-jr-returned-102813-shares-to-6051913)
- 2025-05-21 13:23 UTC [SEC Form 4] [SEC Form 4 filed by Director Bednarski Eric](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-bednarski-eric-6051910)
- 2025-05-21 13:23 UTC [SEC Form 4] [SEC Form 4 filed by Director Heyman Tomas J.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-heyman-tomas-j-6051908)
- 2025-05-21 13:23 UTC [SEC Form 4] [Chief Executive Officer Mahmoud Ramy A returned 314,670 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-mahmoud-ramy-a-returned-314670-shares-to-6051907)
- 2025-05-21 13:22 UTC [SEC Form 4] [SEC Form 4 filed by Director Dempsey Kyle](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-dempsey-kyle-6051902)
- 2025-05-21 12:35 UTC [SEC Form 8-K] [OptiNose Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/optinose-inc-filed-sec-form-8-k-termination-of-a-material-6051750)
- 2025-05-21 12:26 UTC [Mergers & Acquisitions] [Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies](https://www.quantisnow.com/insight/paratek-pharmaceuticals-completes-acquisition-of-optinose-creating-an-expanded-portfolio-6051701)
- 2025-05-16 16:38 UTC [SEC Form 8-K] [OptiNose Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/optinose-inc-filed-sec-form-8-k-submission-of-matters-to-6044796)
- 2025-05-15 20:45 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by OptiNose Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-optinose-inc-6043264)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/OPTN
- Earnings history: https://www.quantisnow.com/earnings/OPTN
- Dividend history: https://www.quantisnow.com/dividends/OPTN
- Insider transactions: https://www.quantisnow.com/insiders/OPTN
- Options chain: https://www.quantisnow.com/options/OPTN
- SEC 8-K filings only: https://www.quantisnow.com/company/OPTN/8-k
- RSS and alerts for OPTN: https://www.quantisnow.com/docs/rss-feeds.md
